Department of Orthopedics, General Hospital "Ippokrateion", Konstantinoupoleos 49, 54642 Thessaloniki, Greece.
Choremeio Research Laboratory, First Department of Pediatrics, National and Kapodistrian University of Athens, Thivon & Levadeias 8, 11527 Athens, Greece.
Medicina (Kaunas). 2023 Jan 10;59(1):141. doi: 10.3390/medicina59010141.
Diabetes mellitus (DM) has a growing prevalence worldwide, even in developing countries. Many antidiabetic agents are used to improve glycemic control; however, in cases of an insufficient outcome, insulin is administered. Yet, the timing of proper insulin administration is still a subject of intense research. To date, there have been no recommendations or guidelines for the use of continuous subcutaneous insulin infusion (CSII) in Type 2 Diabetes Mellitus (T2DM). In the present study, we have performed a meta-analysis to evaluate the use of CSII in patients with T2DM. An extensive literature search was conducted through the electronic databases Pubmed, Clinicaltrials.gov, and Cochrane Central Register of Controlled Trials (CENTRAL) from October 2019-May 2022, for interventional studies related to T2DMI and CSII versus multiple daily injections (MDI). We included articles published in the English language only, yielding a total of thirteen studies. We found better outcomes in patients receiving CSII, in regard to glycated hemoglobin (HbA1c) and total insulin dose. In contrast, fasting plasma glucose and body weight did not show statistically significant differences between the two groups. Our analyses showed that CSII could be beneficial in patients with T2DM in order to achieve their glucose targets.
糖尿病(DM)在全球范围内的患病率不断上升,甚至在发展中国家也是如此。许多抗糖尿病药物被用于改善血糖控制;然而,在疗效不佳的情况下,会给予胰岛素。然而,适当给予胰岛素的时机仍然是一个研究热点。迄今为止,对于 2 型糖尿病(T2DM)患者使用持续皮下胰岛素输注(CSII)尚未有任何建议或指南。在本研究中,我们进行了一项荟萃分析,以评估 CSII 在 T2DM 患者中的应用。我们通过电子数据库 Pubmed、Clinicaltrials.gov 和 Cochrane 对照试验中心(CENTRAL),从 2019 年 10 月至 2022 年 5 月进行了广泛的文献检索,以查找与 T2DMI 和 CSII 与多次每日注射(MDI)相关的干预性研究。我们仅纳入了发表在英语中的文章,共纳入了 13 项研究。我们发现接受 CSII 的患者在糖化血红蛋白(HbA1c)和总胰岛素剂量方面有更好的结果。相比之下,两组之间空腹血浆葡萄糖和体重没有显示出统计学上的显著差异。我们的分析表明,CSII 可能对 T2DM 患者有益,以达到他们的血糖目标。